Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (1) BJM (1) Autor Antunes,Carlos Maurício de Figueiredo (1) Carmo,Ricardo Andrade (1) Coimbra,Lucas Viana (1) El-Emshaty,Wafaa M (1) Elghannam,Doaa M (1) Eltoraby,Ehab E (1) Farah,Kátia de Paula (1) Lambertucci,José Roberto (1) Metwalli,Abd Elhameed A (1) Raafat,Douaa (1) Saudy,Niveen (1) Teixeira,Antônio Lúcio (1) Ávila,Renata Eliane de (1) Mais... Palavra-chave Haemodialysis (2) Egypt (1) End-stage renal disease (1) HCV (1) HCV core antigen (1) Hepatitis C (1) Hyaluronic acid (1) Immunoassay (1) Liver fibrosis (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2011 (1) 2010 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis BJID Ávila,Renata Eliane de; Carmo,Ricardo Andrade; Farah,Kátia de Paula; Teixeira,Antônio Lúcio; Coimbra,Lucas Viana; Antunes,Carlos Maurício de Figueiredo; Lambertucci,José Roberto. BACKGROUND: This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis. METHODS: This is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system. RESULTS: Higher plasma levels were significantly correlated to significant liver fibrosis (METAVIR > F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of... Tipo: Info:eu-repo/semantics/article Palavras-chave: Liver fibrosis; Hyaluronic acid; End-stage renal disease; Haemodialysis; Hepatitis C. Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000400004 Diagnostic performance of an immunoassay for simultaneous detection of HCV core antigen and antibodies among haemodialysis patients BJM El-Emshaty,Wafaa M; Raafat,Douaa; Elghannam,Doaa M; Saudy,Niveen; Eltoraby,Ehab E; Metwalli,Abd Elhameed A. Nosocomial transmission of HCV is a concern in haemodialysis (HD) units worldwide. Diagnosis of HCV infection among dialysis patients is currently based on the detection of anti HCV antibodies by ELISA, and is confirmed by HCV RNA. The average window period between HCV infection and seroconversion with new generations of HCV antibody tests remains approximately 70 days with more prolonged period among dialysis patients. In this study we assessed the diagnostic performance of an immunoassay designed for simultaneous detection of anti HCV antibodies and core antigen in one step in comparison to qualitative RT-PCR and anti HCV antibodies detection test among Egyptian haemodialysis patients. The studied patients were 39 chronic renal failure patients on... Tipo: Info:eu-repo/semantics/article Palavras-chave: Egypt; Haemodialysis; HCV; HCV core antigen; Immunoassay. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822011000100039 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco